CG Oncology Q2 2026: Net loss widens 91% to $79.1M as BLA prep drives R&D spend

Filed August 6, 2026 · Period ending June 30, 2026 · Compared to 10-Q Aug 8, 2025 · ~1 min read

Key Changes

• high

  Net loss widened 91% to $79.1M ($0.90/share diluted, -67%) for Q2 2026 as operating loss grew 77% to $86.4M.

  MD&A: Operating Results verify on EDGAR →
• high

  Court denied ANI's post-trial motions for new trial and judgment as a matter of law on July 16, 2026, affirming jury verdict that CGON owes no 5% royalty on cretostimogene sales; ANI may still appeal.

  Legal Proceedings verify on EDGAR →
• high

  Company raised $391.4M net via ATM in H1 2026 (6.9M shares at $57.56 avg), lifting cash/marketable securities from $661.1M to $1,028.3M; subsequent to quarter-end, expanded ATM capacity by $500M to $750M total.

  Notes: Subsequent Events / MD&A: Liquidity view on EDGAR →